By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ACADIA Pharmaceuticals, Inc. 

3911 Sorrento Valley Boulevard

San Diego  California  92121   U.S.A.
Phone: 858-558-2871 Fax: 858-558-2872


Drug Discovery


Allergan  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Allergan  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Allergan  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.

Sunovion Pharmaceuticals Inc.  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.

Company News
Acadia (ACAD) Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., As Executive Vice President, Head Of Research And Development 11/30/2015 10:19:23 AM
Acadia (ACAD) Appoints Edmund P. Harrigan, M.D., To Board Of Directors 11/30/2015 10:17:27 AM
Acadia (ACAD) Reports Third Quarter 2015 Financial Results 11/6/2015 11:19:18 AM
Acadia (ACAD) To Present At The 24th Annual Credit Suisse Healthcare Conference On November 10, 2015 11/4/2015 11:21:29 AM
Acadia (ACAD) Announces FDA Priority Review Of NUPLAZID (Pimavanserin) New Drug Application For Parkinson’s Disease Psychosis 11/2/2015 10:09:19 AM
Acadia (ACAD) To Announce Third Quarter Financial Results On November 5, 2015 10/29/2015 11:34:57 AM
Acadia (ACAD) To Present At The Ladenburg Thalmann 2015 Healthcare Conference On September 29, 2015 9/23/2015 11:02:19 AM
Acadia (ACAD) Submits New Drug Application For NUPLAZID For The Treatment Of Parkinson’s Disease Psychosis 9/3/2015 10:52:06 AM
Acadia (ACAD) Appoints Steve Davis as CEO 9/3/2015 5:44:43 AM
Acadia (ACAD) Reports Second Quarter 2015 Financial Results 8/7/2015 8:04:03 AM